Cite
HARVARD Citation
Porter, J. et al. (2021). Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development. Expert review of hematology. 14 (7), pp. 633-644. [Online].